Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Portola's AndexXa Antidote For Xarelto And Eliquis Finally On The Way

Executive Summary

FDA approval of an antidote for Factor Xa novel anticoagulants would further drive the already strong uptake of J&J/Bayer's Xarelto and Bristol/Pfizer's Eliquis, analysts say.


Related Content

10 First Approvals To Look Out For In 2018
Portola's Supplementary Approval Paves Way For Belated Bevyxxa Launch
Deal Watch: Gilead Ups Its Investment In CAR-T With Cell Design Buy
Manufacturing Snag May Stall Portola's Bevyxxa Launch
What To Look Out For At ESC, Including Merck's CETP Insights
Portola's Bevyxxa Poised To Capture Niche Novel Anticoagulant Market
COMPASS Success Reinforces J&J/Bayer's Broad Labeling Strategy For Xarelto
Portola Seeks Narrower Label For AndexXa Antidote After FDA Rebuff
BI's Praxbind US Approval May Boost Pradaxa Sales


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts